|
1
|
von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamaguchi K, Okusaka T, Shimizu K, Furuse
J, Ito Y, Hanada K, Shimosegawa T and Okazaki K; Committee for
Revision of Clinical Guidelines for Pancreatic Cancer of the Japan
Pancreas Society, : Clinical Practice Guidelines for Pancreatic
Cancer 2016 From the Japan Pancreas Society: A Synopsis. Pancreas.
46:595–604. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bokemeyer C, Bondarenko I, Hartmann JT, De
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meropol NJ, Schrag D, Smith TJ, Mulvey TM,
Langdon RM Jr, Blum D, Ubel PA and Schnipper LE: American Society
of Clinical Oncology: American Society of Clinical Oncology
guidance statement: The cost of cancer care. J Clin Oncol.
27:3868–3874. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carrato A, García P, López R, Macarulla T,
Rivera F, Sastre J, Gostkorzewicz J, Benedit P and Pérez-Alcántara
F: Cost-utility analysis of nanoparticle albumin-bound paclitaxel
(nab-paclitaxel) in combination with gemcitabine in metastatic
pancreatic cancer in Spain: Results of the PANCOSTABRAX study.
Expert Rev Pharmacoecon Outcomes Res. 15:579–589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurihara T, Kobayashi M, Kogo M, Yoneyama
K, Ito N, Sunaga T, Konishi K, Imawari M, Tobe T and Kiuchi Y:
Cost-effectiveness analysis of chemotherapy with GEM or S-1 for
patients with non-resectable pancreatic cancer. Gan To Kagaku
Ryoho. 37:659–664. 2010.(In Japanese). PubMed/NCBI
|
|
12
|
Gharaibeh M, Bootman JL, McBride A, Martin
J and Abraham I: Economic evaluations of first-Line chemotherapy
regimens for pancreatic cancer: A critical review.
Pharmacoeconomics. 35:83–95. 2016. View Article : Google Scholar
|
|
13
|
Zhou J, Zhao R, Wen F, Zhang P, Tang R, Du
Z, He X, Zhang J and Li Q: Cost-effectiveness analysis of
gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced
pancreatic cancer based on GEST study. Med Oncol. 32:1212015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang
R, Chen H, Zhang J and Li Q: Cost-effectiveness analysis of
treatments for metastatic pancreatic cancer based on PRODIGE and
MPACT trials. Tumori. 3:294–300. 2016. View Article : Google Scholar
|
|
15
|
Kawakami Y: Medical fee points table.
35th. Social Insurance Institute; Tokyo: 2008
|
|
16
|
Pharmaceutical Society, . Insurance drug
encyclopedia. Pharmaceutical Society; Tokyo: 2012
|
|
17
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Furuse J: Up to date of chemotherapy for
pancreatic cancer. Nihon Shokakibyo Gakkai Zasshi. 114:637–643.
2017.(In Japanese). PubMed/NCBI
|
